Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

This study has been terminated.
(Business objectives changed)
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01525225
First received: January 31, 2012
Last updated: June 12, 2014
Last verified: June 2014

January 31, 2012
June 12, 2014
September 2012
June 2013   (final data collection date for primary outcome measure)
  • Maximum observed plasma concentration (Cmax) of Saxagliptin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) of Saxagliptin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Saxagliptin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of 5-Hydroxy Saxagliptin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) of 5-Hydroxy Saxagliptin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of 5-Hydroxy Saxagliptin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Metformin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) of Metformin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 12 hours (AUC(0-12)) of Metformin [ Time Frame: Days 1, 2, 7 and 8 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Saxagliptin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Saxagliptin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Saxagliptin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of 5-hydroxy Saxagliptin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of 5-hydroxy Saxagliptin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 5-hydroxy Saxagliptin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Metformin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Metformin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 12 hours [AUC(0-12)] of Metformin [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Saxagliptin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Saxagliptin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Saxagliptin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Saxagliptin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Saxagliptin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Saxagliptin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Saxagliptin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Saxagliptin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Saxagliptin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of 5-hydroxy Saxagliptin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of 5-hydroxy Saxagliptin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of 5-hydroxy Saxagliptin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of 5-hydroxy Saxagliptin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of 5-hydroxy Saxagliptin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of 5-hydroxy Saxagliptin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 5-hydroxy Saxagliptin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 5-hydroxy Saxagliptin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 5-hydroxy Saxagliptin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Metformin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Metformin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) of Metformin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Metformin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Metformin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Metformin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 12 hours [AUC(0-12)] of Metformin [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 12 hours [AUC(0-12)] of Metformin [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to 12 hours [AUC(0-12)] of Metformin [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01525225 on ClinicalTrials.gov Archive Site
  • Safety: based on medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests [ Time Frame: Up to 8 days ] [ Designated as safety issue: Yes ]
  • Formulation swallowability of Saxagliptin-Metformin FDC tablet, Glucophage® IR tablet and Glucophage® XR tablet [ Time Frame: Days 1, Days 7, and Days 8 ] [ Designated as safety issue: No ]
    Formulation Swallowability: Subjects will respond to a questionnaire regarding their experience swallowing Saxagliptin-Metformin fixed dose combination (FDC) tablet, Glucophage® immediate release (IR) tablet and Glucophage® extended release (XR) tablet. The question regarding ease of swallowability will consist of the following categories for a response: easy, acceptable, difficult, and unable to swallow
Same as current
Not Provided
Not Provided
 
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus Following Oral Administration of Saxagliptin and Metformin XR Fixed Dose Combination Tablet and Co-Administration of Saxagliptin and Glucophage® (Metformin) IR Tablets

The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM)

The primary purpose is to assess the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects aged 10 to 17 years with T2DM

Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Type 2 Diabetes Mellitus
  • Drug: Metformin IR
    Tablet, Oral, 1000 mg, twice daily, 1 day
    Other Name: Glucophage® IR
  • Drug: Saxagliptin
    Tablet, Oral, 5 mg, single-dose, 1 day
  • Drug: Metformin IR
    Tablet, Oral, 1000 mg, twice daily, 5 days
    Other Name: Glucophage® IR
  • Drug: Saxagliptin/Metformin XR FDC
    Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin XR, Single-dose of 2 tablets
  • Drug: Metformin XR
    Tablet, Oral, 500 mg, Single-dose of 4 tablets
    Other Name: Glucophage® XR
Experimental: Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Interventions:
  • Drug: Metformin IR
  • Drug: Saxagliptin
  • Drug: Metformin IR
  • Drug: Saxagliptin/Metformin XR FDC
  • Drug: Metformin XR
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
2
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of T2DM
  • Male and female subjects ages 10-17
  • Body weight ≥50 kg
  • Glycosylated hemoglobin (HbA1c) 6.5 to 10%

Exclusion Criteria:

  • Fasting plasma glucose (FPG) > 240 mg/dL at screening
  • Abnormal renal function
  • Active liver disease and/or significant abnormal liver function
Both
10 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01525225
CV181-153
No
Bristol-Myers Squibb
Bristol-Myers Squibb
AstraZeneca
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP